Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS-NIS)
Latest Information Update: 08 Mar 2023
At a glance
- Drugs Alirocumab (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Therapeutic Use
- Acronyms MARS; MARS-NIS
- Sponsors Sanofi
- 03 Mar 2023 Status changed from active, no longer recruiting to completed.
- 29 Jan 2023 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2022 Planned End Date changed from 31 Oct 2022 to 30 Jan 2023.